Surfactant replacement in spontaneously breathing babies with hyaline membrane disease--a pilot study
- PMID: 2279046
- DOI: 10.1159/000243250
Surfactant replacement in spontaneously breathing babies with hyaline membrane disease--a pilot study
Abstract
In a neonatal unit which, at that time, had no facilities for artificial ventilation, 14 newborn infants with birth weight greater than or equal to 1,500 g fulfilling the diagnostic criteria for severe hyaline membrane disease (HMD) were treated by tracheal instillation of bovine surfactant (200 mg/kg). Twelve of these babies showed increased transcutaneous PO2/FiO2 ratio within 2 min, the average therapeutic response being sustained for at least 72 h. One of the two babies who did not respond to treatment was later diagnosed as a case of group B streptococcal pneumonia. One baby with favorable initial response died from sepsis at the age of 7 days; the other patients survived without sequelae. We conclude that treatment with exogenous surfactant might be considered as an alternative to ventilator treatment in babies with severe HMD.
Similar articles
-
[Treatment of hyaline membrane disease in the preterm newborn with exogenous lung surfactant: a controlled study].Gac Med Mex. 2005 Jul-Aug;141(4):267-71. Gac Med Mex. 2005. PMID: 16164120 Clinical Trial. Spanish.
-
Randomized controlled trial of exogenous surfactant for the treatment of hyaline membrane disease.Pediatrics. 1987 Jan;79(1):31-7. Pediatrics. 1987. PMID: 3540835 Clinical Trial.
-
Artificial surfactant therapy in hyaline-membrane disease.Lancet. 1980 Jan 12;1(8159):55-9. doi: 10.1016/s0140-6736(80)90489-4. Lancet. 1980. PMID: 6101413
-
Review of experimental hyaline membrane disease.Diagn Histopathol. 1981 Jan-Mar;4(1):49-60. Diagn Histopathol. 1981. PMID: 7018865 Review.
-
Perspectives on respiratory distress syndrome of the newborn.Compr Ther. 1989 Dec;15(12):28-34. Compr Ther. 1989. PMID: 2691189 Review.
Cited by
-
Should Minimally Invasive Surfactant Therapy be a Must in Neonatal Intensive Care Units? Pilot Report of Initial Cases in Dubai.Cureus. 2018 Oct 25;10(10):e3495. doi: 10.7759/cureus.3495. Cureus. 2018. PMID: 30648037 Free PMC article.
-
Comparison of the Effectiveness of Beraksurf and Curosurf Exogenous Surfactants in the Treatment of Respiratory Distress Syndrome in Preterm Neonates: A Double-blind Randomized Study in the West of Iran.Curr Pediatr Rev. 2025;21(2):200-206. doi: 10.2174/0115733963271143240403070529. Curr Pediatr Rev. 2025. PMID: 38629362 Clinical Trial.
-
Minimally Invasive Surfactant Administration for the Treatment of Neonatal Respiratory Distress Syndrome: A Multicenter Randomized Study in China.Front Pediatr. 2020 May 7;8:182. doi: 10.3389/fped.2020.00182. eCollection 2020. Front Pediatr. 2020. PMID: 32457854 Free PMC article.
-
Prehospital administration of surfactant to a premature neonate in respiratory distress.Scand J Trauma Resusc Emerg Med. 2019 Oct 29;27(1):95. doi: 10.1186/s13049-019-0664-9. Scand J Trauma Resusc Emerg Med. 2019. PMID: 31665094 Free PMC article.
-
Nebulised surfactant in preterm infants with or at risk of respiratory distress syndrome.Cochrane Database Syst Rev. 2012 Oct 17;10(10):CD008310. doi: 10.1002/14651858.CD008310.pub2. Cochrane Database Syst Rev. 2012. PMID: 23076945 Free PMC article.